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We reviewed any study where 10 or more healthy adults
donated a kidney, and proteinuria, or glomerular filtration
rate (GFR) was assessed at least 1 year later. Bibliographic
databases were searched until November 2005. 31 primary
authors provided additional information. Forty-eight studies
from 27 countries followed a total of 5048 donors. An
average of 7 years after donation (range 1–25 years), the
average 24 h urine protein was 154 mg/day and the average
GFR was 86 ml/min. In eight studies which reported GFR in
categories, 12% of donors developed a GFR between 30 and
59 ml/min (range 0–28%), and 0.2% a GFR less than 30 ml/min
(range 0–2.2%). In controlled studies urinary protein was
higher in donors and became more pronounced with time
(three studies totaling 59 controls and 129 donors; controls
83 mg/day, donors 147 mg/day, weighted mean difference
66 mg/day, 95% confidence interval (CI) 24–108). An initial
decrement in GFR after donation was not accompanied by
accelerated losses over that anticipated with normal aging
(six studies totaling 189 controls and 239 donors; controls
96 ml/min, donors 84 ml/min, weighted mean difference
10 ml/min, 95% CI 6–15; difference not associated with
time after donation (P¼ 0.2)). Kidney donation results in
small increases in urinary protein. An initial decrement
in GFR is not followed by accelerated losses over a
subsequent 15 years. Future studies will provide better
estimates, and identify those donors at least risk of
long-term morbidity.
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A critical reduction in renal mass may result in remnant
single nephron hyperfiltration, with associated proteinuria
and an accelerated loss of kidney function.1 However, the
long-term implications of donating a kidney remain
uncertain. The primary questions of this review were: (1)
What proportion of kidney donors develop proteinuria or a
glomerular filtration rate (GFR) less than 60 ml/min? (2) Do
kidney donors, compared to healthy non-donor controls,
have a higher urinary protein? (3) Do kidney donors
compared to controls have an accelerated loss of GFR after
the initial decrement from their nephrectomy? Reasons for
different estimates in the literature were also explored using
meta-regression.
RESULTS
Finding studies
From screening 2886 citations, 262 full-text articles
were retrieved, and 62 studies met our criteria for
review. The chance-corrected agreement between two in-
dependent reviewers for article inclusion was good
(kappa¼ 0.83). We subsequently excluded two studies which
reported hypertension outcomes but not renal outcomes.2,3
Some study cohorts contained a proportion of outcome
assessment donors with hypertension, overt proteinuria, or a
GFR less than 80 ml/min (per 1.73 m2) before the time of
surgery, and did not separate reported outcomes from
healthy donors. As this review focused on kidney function
in potential donors in best health, we excluded such
studies.4–15
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Description of studies, methods, donors, controls, and
outcome assessment
Forty-eight studies from 27 countries followed a total of
5048 donors an average of 7 years (median 6, range 1–25
years after donation), and were published from 1973 to
2005 (Tables 1 and 2).16–63 Forty-three primary authors
were successfully contacted, and 31 kindly provided addi-
tional data or confirmed the accuracy of abstracted
data.16,18–20,24–27,31–40,42,44,46,47,51,53,55,57–59,61–63
Of the 48 studies, 21% prospectively followed donors in
time, 15% had donor outcomes measured at fixed year(s)
post-donation, 91% defined how proteinuria was measured,
96% defined how renal clearance was measured, 67%
provided a definition of clinical proteinuria, and 90%
described the total number of donors from which the
participating sample was drawn. When described, on average
31% of surviving donors eligible to participate in each study
were lost to follow-up (range 0–79%). Four studies described
the characteristics of donors lost to follow-up.58,59,61,63
Before surgery, over all studies, the average age of donors
was 41 years (in the various studies average age ranged from
26 to 59 years), the average serum creatinine was 81 mmol/l
Table 1 | Characteristics of long-term renal prognosis studies of living kidney donors
Sourcea Primary location
No. of
donors
Years of
donation
Prospective
study
Patient age,
mean (range), yearsb
Women
(%)
Johnson et al.16 Boston, USA 78 2000–2003 No 44 (22–72) 60
Mimran et al.17 Montpellier, France 18 y Yes 48 (20–62) 56
Sobh et al.18 Mansoura, Egypt 45 y No 26 (22–64) 53
Friedlander et al.19 Iowa City, USA 12 1980–1985 Yes 36 (19–61) 75
Kostakis et al.20 Athens, Greece 255 1986–1996 No 60 (24–82) 74
Beekman et al.21 Leiden, Netherlands 47 1981–1988 Yes 36 (20–66) 49
Tondo et al.22 Parma, Italy 10 1986–1996 No 46 (...) 30
Hida et al.23 Bohseidai, Japan 34 1976–1981 Yes 56 (24–66) 59
Rivzi et al.32 Karachi, Pakistan 736 1986–2003 No 34 (...) 50
Abomelha et al.24 Riyadh, Saudi Arabia 70 1979–1989 Yes 32 (18–58) 29
Liu et al.25 St. Leonards, Australia 17 y No 48 (27–61) 76
Edgren et al.26 Helsinki, Finland 46 y No ... (20–74) 70
Siebels et al.27 Munich, Germany 122 1994–2001 Yes 52 (21–77) 80
Basseri et al.28 Teheran, Iran 87 y No 34 (17–58) 43
Enger29 Oslo, Norway 13 1963–1971 Yes 48 (29–65) 69
Ghahramani et al.30 Shiraz, Iran 136 1988–1997 Yes 34 (...) y
Mendoza et al.31 Mexico City, Mexico 152 1968–1985 No 28 (...) 57
Gonzalez et al.33 New York, USA 25 1976–1987 No 36 (20–58) 68
Fourcade et al.34 Lyon, France 99 1967–1994 No 38 (18–57) 54
Dunn et al.35 Nashville, USA 250 1970–1984 Yes 34 (18–67) 44
ter Wee et al.36 Groningen, Netherlands 15 1983 No 38 (...) 40
O’Donnell et al.37 Johannesburg, South Africa 33 1966–1984 No 38 (...) 45
Laskow et al.38 Birmingham, USA 48 y No 40 (...) 52
Miller et al.39 New York, USA 47 1984 No 40 (18–60) 68
Rodriguez-Iturbe et al.40 Maracaibo, Venezuela 25 y No ... (20–60) 44
Marekovic et al.41 Zagreb, Yugoslavia 50 1973–1990 No 50 (23–69) 34
Prandini et al.42 Bologna, Italy 32 1970–1980 No 42 (22–54) 72
Sato et al.43 Sendai, Japan 97 1968–1989 No 60 (37–77) y
Chen et al.44 Taipei, Taiwan 76 1980–1991 No 44 (18–66) 59
D’Almeida et al.45 Porto Alegre, Brazil 110 1977–1993 No 36 (...) y
Gracida et al.46 Mexico City, Mexico 628 1992–2001 Yes 36 (18–64) 49
Schostak et al.47 Berlin, Germany 53 1974–2002 No 48 (...) 56
Horcickova et al.48 Prague, Czech Republic 93 1966–1999 No 50 (26–69) 68
Lumsdaine et al.49 Edinburgh, UK 47 1986–2000 No ... (...) y
Wiesel et al.50 Hildelberg, Germany 67 1967–1995 No ... (...) y
Najarian et al.51 Minneapolis, USA 472 1963–1980 No 36 (18–68) 69
Toronyi et al.52 Budapest, Hungary 30 1973–1996 No ... (...) 83
Haberal et al.53 Ankara, Turkey 102 1975–1996 No 42 (21–65) 56
Undurraga et al.54 Santiago, Chile 74 y No 40 (...) 73
Talseth et al.55 Oslo, Norway 70 1969–1974 No 46 (33–55) 47
Eberhard et al.56 Hannover, Germany 29 1973–1990 No ... (...) 76
Fehrman-Ekholm et al.57 Stockholm, Sweden 348 1964–1995 No 50 (22–76) 74
Williams et al.58 Philadelphia, USA 38 y No 40 (19–59) 68
Watnick et al.59 New Haven, USA 29 1969–1978 No ... (...) 45
Mathillas et al.60 Go¨teborg, Sweden 46 1965–1973 No 46 (23–70) 57
Saran et al.61 Newcastle, UK 47 1963–1982 No ... (...) 51
Iglesias-Marquez et al.62 San Juan, Puerto Rico 20 1977–1980 No 42 (...) 60
Goldfarb et al.63 Cleveland, USA 70 1963–1975 No 40 (19–57) 59
Ellipses (y) indicate not reported.
aStudies are arranged by the average number of years after donation.
bAge is reported at the time of donation.
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(0.92 mg/dl, range 51–100 mmol/l), the average GFR was
111 ml/min (range 91–132), the average systolic blood
pressure was 121 mmHg (range 107–132), and the average
diastolic blood pressure was 77 mmHg (range 75–79). No
donors had overt proteinuria before surgery. The average
pre-donation urinary protein was quantified in six studies at
95 mg per day (range 55–124).19,32,41,44,58,63
Eleven of the studies also collected data on suitable non-
donor controls to determine if increases in urinary protein
and reductions in GFR after donation were above that
Table 2 | Long-term renal prognosis studies of living kidney donors
Pre-donation
Post-donation
Change
GFR, ml/min Proportion Years after
Proteinuriab GFR, ml/min (per 1.73 m2)b
GFR, ml/min
Sourcea
(per 1.73 m2),
mean (s.d.)b
lost to
follow-up, %
donation,
mean (range)a %
mg, mean
(s.d.)
60–80,
%
30–59,
%
mean
(s.d.)
(per 1.73 m2),
mean (s.d.)b
Johnson et al.16 120 (15) 0 1 (1–1) y y y y y y
Mimran et al.17 126 (36) y 1.2 (y) y y y y 73 (17) 38 (11)c
Sobh et al.18 133 (28) y 1.9 (1–10) 20 y y y 83 (37) 50 (18)c
Friedlander et al.19 116 (19) 46 2 (1–3) y 81 (66) y y 77 (21) 36 (21)
Kostakis et al.20 y 24 2 (y) 7 y y y y y
Beekman et al.21 110 (19) 0 2 (y) 4 y y y 89 (25) 21 (22)d
Tondo et al.22 y 0 2.1 (0.2–5) 0 y y y y y
Hida et al.23 92 (18) 0 2.8 (0.5–5) 0 y y y 75 (20) 17 (19)d
Rivzi et al.32 101 (28) 40 3 (0.5–18) 5 139 (248) y 7 87 (20) 14 (25)d
Abomelha et al.24 118 (21) 64 3.1 (1–10) 1 y y y 82 (15) 36 (10)c
Liu et al.25 y y 3.1 (0.1–10) 0 y y y 81 (16) y
Edgren et al.26 105 (26) 28 3.2 (0.2–6) y y y y 80 (17) 24 (7)c
Siebels et al.27 y 24 3.2 (0.1–5) 5 y y y y y
Basseri et al.28 151 (y) 0 3.2 (1–8) 1 y y y 105 (y) 46 (y)
Enger29 110 (8) 0 3.5 (0.5–8) 0 y 23 15 84 (8) 26 (7)c
Ghahramani et al.30 y 21 3.6 (0.3–9) 33 y y y y y
Mendoza et al.31 130 (37) 15 3.7 (0.1–12) 1 y 0 0 117 (32) 13 (35)d
Gonzalez et al.33 y 43 4.2 (0.5–12) 4 y y y y y
Fourcade et al.34 115 (15) 0 4.3 (0.1–19) 29 y 41 6 80 (12) 35 (12)
Dunn et al.35 129 (31) 18 4.4 (0.5–15) 3 y y y 85 (33) 43 (32)d
ter Wee et al.36 111 (21) 38 4.9 (1.5–13) 33 150 (232) y y 76 (14) 35 (18)d
O’Donnell et al.37 108 (16) 62 5.8 (3–18) 6 y y y 100 (22) 8 (20)d
Laskow et al.38 y y 5.9 (y) 2 y y y y y
Miller et al.39 y 77 6 (2–15) 41 144 (121) y y y y
Rodriguez-Iturbe et al.40 y 7 6 (1–11) y y y y 115 (43) y
Marekovic et al.41 103 (30) y 6.1 (1–15) 0 72 (13) y y 86 (34) 17 (32)d
Prandini et al.42 y 22 6.2 (5.2–17) 0 y y y 99 (25) y
Sato et al.43 y 3 6.3 (2–17) 12 y y y y y
Chen et al.44 y 0 6.4 (y) y 194 (89) y y y y
D’Almeida et al.45 y 67 6.6 (1–14) 18 142 (121) y y 87 (45) y
Gracida et al.46 115 (y) 0 6.7 (0.5–10) 0 y y y 79 (y) 36 (11)c
Schostak et al.47 y 48 6.9 (y) 23 y y y y y
Horcickova et al.48 y y 7.1 (0.2–31) 30 y y y y y
Lumsdaine et al.49 y 69 7.1 (y) 0 y y y y y
Wiesel et al.50 y 43 8 (y) 19 y y y y y
Najarian et al.51 y 25 8.3 (1–19) 6 y y y y y
Toronyi et al.52 y 62 8.9 (y) 0 y y y 98 (y) y
Haberal et al.53 109 (9) 32 10.2 (0.7–22) 4 y y y 97 (19) 12 (16)d
Undurraga et al.54 92 (22) y 10.9 (1–21) 18 y y y 81 (22) 10 (3)c
Talseth et al.55 108 (26) 5 11 (10–12) 24 y y y 87 (29) 21 (28)d
Eberhard et al.56 y 79 11.1 (5–20) 3 y 38 28 75 (22) y
Fehrman-Ekholm et al.57 y 13 12.5 (2–33) 12 y y y 64 (13) y
Williams et al.58 106 (30) 32 12.6 (10–18) 32 135 (174) y 8 85 (23) 20 (27)d
Watnick et al.59 y 19 13 (9–18) 14 y y 0 85 (16) y
Mathillas et al.60 y 13 14.9 (10–20) 26 306 (232) 52 20 y y
Saran et al.61 y 21 19.6 (13–31) 34 y 36 19 77 (y) y
Iglesias-Marquez et al.62 126 (y) y 20 (y) 5 y y y 98 (y) 27 (16)c
Goldfarb et al.63 102 (41) 47 25 (20–32) 20 230 (60) y y 73 (23) 29 (36)d
GFR, glomerular filtration rate.
Ellipses (y) indicate not reported.
aStudies are arranged by the average number of years after donation.
bA summary of various methods to assess GFR and proteinuria are presented in the ‘Results’ section.
cVariance estimates were derived from t-statistics.
dVariance estimates were imputed using the formula described in the ‘Materials and methods’ section.
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attributable to normal aging.18,35,37,39,45,51,54,55,58–60 Controls
were healthy volunteers, or individuals under evaluation as
potential donors, with similar age, sex, race, and / or, height
distributions as donors. In all studies control groups were
assembled at the time of donor follow-up evaluation. With
the exception of a single study,39 none appeared to follow
controls prospectively from the time of donor surgery.
Forty-one studies described the method of urine protein
quantification, which usually was a timed (i.e. 24 h) urine. Other
methods included a random urine protein,16,23,25,28,29,49,54,57,62
dipstick,27,47 a timed urine albumin,18,46,51,59,61 a random urine
albumin to creatinine ratio34 and a first am urine albumin
concentration.56 Thresholds for clinical proteinuria varied,
and included 4100,37,53 4150,35,39,48,55,58,59,63 4200,45
4300,24,30,32,33,42,43,46,56,60 4500,21 or 4600 mg20 of protein
per day, or various levels on urinary dipstick.18,23,25,27,28,47,49,54,57
Forty-four studies described the method of GFR estima-
tion, which usually was a timed urine creatinine clear-
ance.17–19,23–25,29–32,37,40,41,45,48,49,51,55,58,62,63 Other methods
included the use of inulin or radioisotopes,20,34,36,46,52,53,59–61
or a predictive equation for GFR.28,54,56,57 Ten studies only
described a serum creatinine result.16,22,27,33,35,38,39,44,47,50 In
61% of studies the reported GFR was standardized to 1.73 m2
of body surface area.
Death, kidney failure, and cardiovascular disease
Thirty-three studies described the number of donors who
died during follow-up, which ranged from 0 to 16% of the
study cohort. In one of these studies, a total of two donors
died with kidney failure.63 A total of 10 donors from eight
different studies were living with kidney failure at the time of
last assessment.32,39,43,48,51,57,61,63 Seven studies described a
proportion of donors who developed cardiovascular disease
during follow-up,46,48,55–57,60,63 although these events were
not systematically assessed.
Incidence of proteinuria
The incidence of clinical proteinuria after donation was
quantified in 42 studies, which followed 4793 living donors
an average of 7 years (range 2–25 years). There was signifi-
cant heterogeneity between the studies (Po0.0001). Some
studies reported an incidence of proteinuria over
20%,30,34,36,39,47,48,55,58,60,61 whereas in others the incidence
was less than 5%.21–25,28,29,31–33,35,38,41,42,46,49,52,53,56 (Table 2).
The pooled incidence of proteinuria was 12% (95%
confidence interval (CI) 8–16%). These results were similar
in a supplementary analysis which only considered those nine
studies which consistently defined proteinuria as 4300 mg/
day based on 24 h urine.24,30,32,33,42,43,46,56,60 The pooled
incidence of proteinuria among these nine studies which
followed a total of 1799 donors for 7 years was 10% (95% CI
7–12%).
Risk of proteinuria
Three studies compared a total of 129 donors to 59 controls
on 24-h urine protein, to determine if increases in
proteinuria after donation were above that possibly attribu-
table to normal aging (Figure 1).45,58,60 Proteinuria appeared
to be increased after donation in each of these three studies,
although the CIs were wide. There was no evidence of
statistical heterogeneity between these three studies, suggest-
ing they could have been theoretically sampled from a
common distribution (w2 0.51, P¼ 0.78, I2¼ 0%). Thus
the results were mathematically pooled, to establish a
more precise estimate. The 24-h urine protein was higher
in donors compared to controls an average of 11 years
after donation (controls 83 mg/day, donors 147 mg/day,
weighted mean difference 66 mg/day, and 95% CI 24–108).
This difference increased with the time from donation
(Po0.001).
Four studies compared a total of 146 donors to 105
controls on 24-h urine albumin (Figure 2).45,55,59,60 There
was evidence of extreme statistical heterogeneity between
these studies; thus results were not mathematically pooled (w2
57.4, Po0.00001, I2¼ 95%). In two of the four studies, 24-h
urine albumin was approximately 56 mg higher in donors
compared to controls 14 years after donation.59,60
Two studies assessed the risk of microalbuminuria after
kidney donation in a total of 67 donors and 51 controls at
2 and 13 years after donation (Figure 2).18,59 The mathema-
tically pooled result should be interpreted with the under-
standing that notable heterogeneity was present between
these studies (w2 2.3, P¼ 0.13, I2¼ 56%). The pooled risk of
microalbuminuria after kidney donation was 3.9 (95% CI
1.2–12.6).
Kidney function after donation
Among the 36 studies of 3529 donors which reported a post-
donation serum creatinine or GFR with an estimate of
variance, the average time after donation was 6 years, the
average serum creatinine was 98 mmol/l (1.11 mg/dl, range
58–119 mmol/l), the average GFR was 86 ml/min (per 1.73 m2)
(range 64–117). In 22 studies where it was described, the
average decrement in GFR after donation was 26 ml/min
(per 1.73 m2) (range 8–50). Nine studies reported a post-
donation GFR which could be assessed in categories
(Table 2).29,31,32,34,56,58–61 The average post-donation GFR
in these studies did not differ from the remaining studies (88
vs 85 ml/min (per 1.73 m2), P¼ 0.4). In these eight studies a
mean of 10 years after donation, 40% of donors developed a
GFR between 60 and 80 ml/min (per 1.73 m2) (range
23–52%), 12% of donors developed a GFR between 30 and
59 ml/min (per 1.73 m2) (range 0–28%), and 0.2% a GFR less
than 30 ml/min (per 1.73 m2) (range 0–2.2%). These results
were no different in a supplementary analysis which only
considered those studies where the GFR was measured, rather
than estimated from a predictive equation.
Risk of reduced kidney function
Controlled studies were reviewed to determine if the initial
decrement in GFR after nephrectomy was accompanied by
subsequent accelerated loss in GFR over that anticipated with
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Figure 1 | Controlled studies of proteinuria after kidney donation. The size of each square is inversely proportional to the variability of the
study estimate. *Studies are arranged by the average number of years after donation. zMicroalbuminuria was assessed by 24 h urine.
wMathematically pooled results are not presented graphically because of statistical heterogeneity between studies. See ‘Results’ section.
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normal aging. There was no statistical heterogeneity between
those where the average follow-up was at least 5 years after
donation (w2 1.49, P¼ 0.91, I2¼ 0%) and these results were
mathematically pooled (Figure 2).37,45,51,54,58,59 The pooled
post-donation GFR was 10 ml/min (per 1.73 m2) lower in
donors compared to controls (six studies totaling 189
controls and 239 donors; controls 96 ml/min, donors
84 ml/min, weighted mean difference 10 ml/min, and 95%
CI 6–15). The difference was similar across studies,
irrespective of the time from donation (P¼ 0.2).
Pre-donation prognostic features
Among healthy donors, the primary studies reported a
number of prognostic pre-donation features associated with a
higher proteinuria or lower GFR after donation. Within
donors many of these features clustered together, and
multivariate regression was only reported in a minority of
studies. Potential true associations may also have gone
undetected, as the sample size of many studies was small.
In the primary studies, compared to women, men were
reported to have larger increases in proteinuria after
donation.58,59,63 Although there was a nonsignificant trend
in one study,30 there was no reported association between
the time after donation and the amount of proteinuria at
last follow-up.39,56,58,59 Neither donor age at the time of
surgery,16,39,55,58,63 nor pre-donation blood pressure55 was
associated with proteinuria after donation.
When we conducted study level meta-regression, average
age at donation, the proportion of female donors, and the
average pre-donation blood pressure were not associated
with proteinuria after donation (P-values ranged from 0.22
to 0.69).
In the primary studies, compared to men, women were
reported to have a lower GFR both before and after
donation.61,63 There was no gender differences in the
decrement in GFR after donation.63 Similarly, compared to
those who were younger, older donors demonstrated a lower
GFR both before and after donation.34,46,63 In older donors,
the decrement in GFR after donation tended to be
smaller,46,61 larger16,26,34,39,55,57 or no different than younger
individuals.63 Pre-donation obesity,46 plasma uric acid,46 and
serum cholesterol46 were not associated with the post-
donation GFR. Black and white donors were similar in their
renal response to donation.38 The time after donation was
not associated with post-donation GFR or change in
GFR.25,27,56,58,59 In one study, a higher pre-donation blood
pressure was associated with a larger decrement in GFR after
donation.55
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When we conducted study level meta-regression, older age
at the time of donation was associated with both lower pre-
and post-donation GFR (explaining 26 and 38% of the
between study variability respectively). For example, donors
aged 25 years old at the time of donation developed an
approximate post-donation GFR of 94 ml/min (per 1.73 m2),
whereas in donors aged 55 it was 74 ml/min (per 1.73 m2).
However, the change in GFR after donation was not
statistically associated with donor age at the time of
donation. The proportion of female donors, and average
pre-donation systolic or diastolic blood pressure were not
associated with change in GFR or post-donation GFR
(explaining 2–7% of the between study variability).
Prognostic methods features
Studies with more donors lost to follow-up demonstrated a
somewhat larger decrement in GFR after donation (explain-
ing 22% of the between study variability). The average
follow-up time after donation was associated with the
proportion of donors who developed clinical proteinuria.
Otherwise, none of the other methodological features tested
in meta-regression were associated with outcomes in multi-
variate analyses (P-values ranged from 0.09 to 0.68).
DISCUSSION
In this quantitative review, kidney donation resulted in small
increases in urinary albumin, which increased with the time
after donation. Many would consider this indicative of single
nephron hyperfiltration from a reduced renal mass. Whether
such hyperfiltration leads to a progressive deterioration in
kidney function has been the subject of many debates. Ten
years after nephrectomy, donors had a GFR that was 10 ml/
min lower compared to controls. In addition approximately
12% of donors developed a GFR less than 60 ml/min during
follow-up. However, after the initial decrement in GFR from
the nephrectomy, there was no evidence of an accelerated loss
in GFR over that anticipated with normal aging.
Strengths and weaknesses of this review
This review summarized 48 single center studies, and shares
similar strengths and weaknesses to a parallel review
conducted on hypertension risk in living donors.64 In brief,
since the last quantitative review on this topic, we identified
35 new articles.65 Relevant data was rigorously identified and
abstracted, articles were translated, information was clarified
with a majority of primary study authors, and reasons for
diversity in the published literature were explored. We
justified reasons for mathematically combining certain
results. However, results from any meta-analysis are inher-
ently limited by the quality of the primary studies. As
described, on average about one-third donors were lost to
follow-up. Most of the studies also did not have an internal
control group, making it difficult to interpret the donor
results. A proportion of donors would have developed certain
medical conditions even if they had not donated a kidney.
Those studies, which did have a control group often,
recruited participants from the general population. Such
individuals are not as fit as donors, which may have biased
towards demonstrating no increased risk of certain medical
conditions after donation. Similarly, long-term sequelae after
donation may be underreported, if transplant centers were
reluctant to describe significant morbidity after this perceived
iatrogenic event.66 Among the controlled studies proteinuria
and GFR were assessed in a similar manner in both donors
and controls, with observed differences suggesting a true
difference between the groups. However, inconsistent meth-
ods of measuring and reporting proteinuria and renal
function in the primary studies complicate the interpretation
of these results. For example, only a few studies reported
post-donation GFR in categories consistent with modern
cutoff points used to assess renal function.67 In most studies
it was unclear whether donors who developed a low GFR also
had concurrent hypertension and proteinuria.
Renal sequelae, donor selection, and long-term surveillance
The proportion of donors who develop clinical proteinuria
appears to be higher than expected in the general population
– whereas kidney donation increases urinary protein often
within the range considered normal, approximately 10% of
donors exceed a threshold of 300 mg/day over a subsequent
decade. Similarly, about 12% of donors develop a GFR less
than 60 ml/min over this same period. Although some
donors may have been predestined to develop such a GFR
even if they had not donated a kidney, a decrement of 10 ml/
min after their nephrectomy likely hastens this event. Thus
the central question remains – what is the prognostic
significance of proteinuria or reduced kidney function in
this patient population? In the general population, low GFR
and proteinuria may be signs of systemic atherosclerosis, and
both are associated with concurrent metabolic disturbances,
future premature mortality, cardiovascular disease, and
kidney failure.68–70 For this reason some, but not all, consider
a GFR of 30–59 ml/min as the pathologic state of stage 3
chronic kidney disease.67,71 However, kidney donors develop
reduced kidney function or low-grade proteinuria through a
different mechanism, and their prognostic significance in this
segment of the population remains uncertain. Indeed, donors
undergo rigorous evaluation and selection, and their
incidence of death is lower than the general population.72
Thus, without evidence of adverse health outcomes, small
changes in measurements of proteinuria or GFR should not
be the sole reason for deterring a practice which benefits
recipients, donors, and society.
Living donors whose data were summarized in this review
demonstrated no evidence of hypertension, proteinuria or
reduced kidney function before donation. However, in the
current era, the eligibility criteria for donation are being
extended, and some centers now accept potential donors with
a GFR less than 80 ml/min.73 It is important to consider that
many donors may have a genetic predisposition to develop-
ing kidney disease, and a total of 10 donors (0.2%, one in 500
donors) in this review were reported to have developed
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kidney failure requiring dialysis. Thus the acceptance of
living donors at potentially higher incremental risk for future
adverse events remains contentious. A decision to proceed in
such cases should be made by an experienced transplant team
that carefully considers donor and recipient preferences, in
conjunction with judicious use of the evidence summarized
here for healthy donors. It also remains prudent to counsel all
donors, irrespective of their pre-donation health state, on
modifiable risk factors which prevent future renal and
cardiovascular disease.74,75
Unlike in the case of blood pressure measurements,
routinely screening the general population to detect an
elevated serum creatinine or the presence of urine protein is
not recommended. However, living donors are a group who
may be at higher risk of renal sequelae, and to prevent future
morbidity it remains unclear which renal screening tests
should be performed, how long donors should be followed,
and which health care providers should be responsible for
such follow-up. Some transplant centers assume responsi-
bility for follow-up, whereas others examine donors once or
twice before returning care back to the primary physician.
Some advocate limiting renal follow-up to 5 years, to prevent
the perception that being a donor is pathological.73 The
results summarized here support the safety of live kidney
donation. However, until the prognostic significance of low-
grade proteinuria or reduced kidney function in some kidney
donors is better understood, we would advocate for a lifetime
of annual serum creatinine and urine protein screening.
Future research
Results from this quantitative review will be best confirmed
by the completion of a large, prospective, multi-center cohort
study with representative numbers of donors and appropriate
controls followed for extended periods of time.76,77 Inclusion
of racially-diverse, older and genetically unrelated donors,
and controls will help define if there are any differential
effects of donation among such individuals. Finally, by assess-
ing definitive outcomes such as death and cardiovascular
disease, the prognostic significance of small increases in
urinary protein or reduced kidney function after donation
will be better understood.
MATERIALS AND METHODS
Studies eligible for review
We included a study in any language where 10 or more healthy
adults donated a kidney, and either proteinuria or GFR was assessed
at least 1 year later.
Finding relevant studies, data abstraction, and statistical
analysis
We recently published a parallel review on the risk of hypertension
after living kidney donation, where methods used in this review are
fully described.64 In brief, until November 2005 we screened relevant
citations from multiple sources including MEDLINE, EMBASE, and
Science Citation Index bibliographic databases. Pairs of reviewers
independently evaluated the eligibility of each full-text article, and
data was abstracted in duplicate. Studies in languages other than
English were translated. When data from the same group of donors
were described in multiple publications,64 we cited the most
representative publication of the greatest number of donors with
longest follow-up. We attempted to contact primary authors of all
included studies to confirm data and provide missing information.
Reviewer agreement on study eligibility was quantified using the
kappa statistic. Variance estimates for pre- and post-donation
changes GFR were not reported in a majority of studies. If not
reported, variance estimates were derived from t-statistics when
available. Otherwise variance estimates were calculated with
SED ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE2pre þ SE2postð2rDSEpreSEpostÞ
q
, where rD represents
the correlation between the pre- and post-donation GFR measure-
ments.78 For the two studies that did report pre donation, post-
donation and change variance estimates, we calculated an average
correlation coefficient of 0.59 for GFR. Thus we utilized a
correlation of 0.5 to impute missing change variance estimates in
the final meta-regression. We performed sensitivity analyses to this
choice of correlation and results were qualitatively similar. For those
few studies, which only reported a range of donor follow-up, we
considered the average follow-up time as the midpoint of the
provided range.
For this study level meta-analysis, the Q-statistic was used to
determine if between study heterogeneity was present, with a
P-value of o0.1 considered statistically significant. The I2-statistic
was used to quantify the magnitude of heterogeneity, with value of
0–30%, 31–50% and greater than 50% representing mild, moderate,
and notable heterogeneity respectively.79 When justified, results were
mathematically pooled using techniques which accounted for within
and between study heterogeneity (random effects method).80–82
Although creatinine clearance is conceptually different from GFR, it
is commonly used as an estimate of GFR and therefore was used
interchangeably for this outcome. Although some studies reported
GFR standardized to body surface area, others did not. In pooled
estimates we combined all studies irrespective of whether GFR was
standardized to body surface area, and reported the unit as ml/min
(per 1.73 m2).
Reasons for diversity in primary study estimates were explored
using univariate and multivariate meta-regression of donor cohorts:
mixed models for continuous outcomes (SAS PROC MIXED) and
logistic normal random effects models for binary outcomes (SAS
PROC NLMIXED). At the study level, the association between the
following donor characteristics and outcomes of proteinuria or
lower GFR after donation were considered: older age, a higher pre-
donation blood pressure, and a lower pre-donation GFR. We
hypothesized that these factors would be associated with increased
proteinuria or a lower GFR after donation.83,84 Features of study
methodology associated with renal outcomes after donation were
also considered. The methodological features tested in meta-
regression were whether the study was conducted prospectively,
the duration of follow-up, the proportion of donors lost to follow-
up, and the method by which renal function was assessed.
The explanatory ability of each factor was quantified by the
proportion of between study variability on the logit scale for binary
outcomes, and the proportion of between study variability for
continuous outcomes.82 A two-tailed Pp0.05 was considered
statistically significant for binary outcomes, whereas for continuous
outcomes statistical significance was inferred by the proportion of
variability explained by the factor and from the size of residual
variance.82 Best fit lines in meta-regression graphs were created
using generalized estimating equations (SAS PROC GENMOD).85,86
Generalized estimating equations models used estimates from the
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meta-regression models as the input values, and were weighted by
the variance of each estimate. An exchangeable correlation matrix
was assumed for all generalized estimating equations models. For
models of binary outcomes, a binomial distribution with the logit
link was used and for models of continuous outcomes, a normal
distribution with the identity link was used. The 95% CI for each
best fit meta-regression line was computed as g1ðx0j b^	 z1a=2sxÞ,
where g is the link function, xj is the vector of covariates, z is the
percentile of the normal distribution, and sx is the estimate s.e. of
the linear predictor. The variance estimate of the linear predictor
was calculated as s2x ¼ x
0
jSxj, where S is the empirical covariance
matrix. All analyses were conducted using SAS 8.02 (SAS Institute
Inc., Cary, NC, USA) and Revman 4.2 (Cochrane Collaboration,
Oxford, England). Results were graphed in R 2.0.1 (R Foundation
for Statistical Computing, Vienna, Austria).
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